Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343445 · ClinicalTrials.gov registry record · Phase 2
Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)
A Phase 2 study, sponsored by Parion Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT02343445: Completed Phase 2 study, sponsored by Parion Sciences.
NCT02343445 is a Phase 2 study that has completed, run by Parion Sciences. The registered enrollment target is 142 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02343445, a Phase 2 study, has completed, sponsored by Parion Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
The goal of the study is to evaluate the safety and tolerability of P-1037 and to determine whether the combination of P-1037 with hypertonic saline or P-1037 alone has a greater effect on lung function in patients with CF than placebo (0.17% saline).
Primary Outcome
number of adverse events of P-1037 in treatment groups
Interventions
- DRUG Saline
- DRUG Hypertonic Saline
- DRUG P-1037
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
What the finished NCT02343445 record still lists
NCT02343445 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT02343445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02343445 about?
NCT02343445 is a clinical study titled "Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)". The goal of the study is to evaluate the safety and tolerability of P-1037 and to determine whether the combination of P-1037 with hypertonic saline or P-1037 alone has a greater effect on lung function in patients with CF than placebo (0.17% saline).
What is the current status of trial NCT02343445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2015-04. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02343445?
The interventions under investigation include: Saline (DRUG), Hypertonic Saline (DRUG), P-1037 (DRUG).
Who is sponsoring clinical trial NCT02343445?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02343445's enrollment target sits among peer trials
142 507th of 2000 higher than 1,491 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia